OtherConsensus

2022 Chinese expert consensus and guidelines on clinical management of toxicity in anti-CD19 chimeric antigen receptor T-cell therapy for B-cell non-Hodgkin lymphoma

Ping Li, Yang Liu, Yun Liang, Jian Bo, Sujun Gao, Yongxian Hu, Yu Hu, He Huang, Xiaojun Huang, Hongmei Jing, Xiaoyan Ke, Jianyong Li, Yuhua Li, Qifa Liu, Peihua Lu, Heng Mei, Ting Niu, Yongping Song, Yuqin Song, Liping Su, Sanfang Tu, Jianxiang Wang, Depei Wu, Zhao Wang, Kailin Xu, Zhitao Ying, Qingming Yang, Yajing Zhang, Fengxia Shi, Bin Zhang, Huilai Zhang, Xi Zhang, Mingfeng Zhao, Weili Zhao, Xiangyu Zhao, Liang Huang, Jun Zhu, Wenbin Qian, Weidong Han and Aibin Liang
Cancer Biology & Medicine February 2023, 20 (2) 129-146; DOI: https://doi.org/10.20892/j.issn.2095-3941.2022.0585

Abstract

Adoptive cellular immunotherapy with chimeric antigen receptor (CAR) T cells has emerged as a novel modality for treating relapsed and/or refractory B-cell non-Hodgkin lymphoma (B-NHL). With increasing approval of CAR T-cell products and advances in CAR T cell therapy, CAR T cells are expected to be used in a growing number of cases. However, CAR T-cell-associated toxicities can be severe or even fatal, thus compromising the survival benefit from this therapy. Standardizing and studying the clinical management of these toxicities are imperative. In contrast to other hematological malignancies, such as acute lymphoblastic leukemia and multiple myeloma, anti-CD19 CAR T-cell-associated toxicities in B-NHL have several distinctive features, most notably local cytokine-release syndrome (CRS). However, previously published guidelines have provided few specific recommendations for the grading and management of toxicities associated with CAR T-cell treatment for B-NHL. Consequently, we developed this consensus for the prevention, recognition, and management of these toxicities, on the basis of published literature regarding the management of anti-CD19 CAR T-cell-associated toxicities and the clinical experience of multiple Chinese institutions. This consensus refines a grading system and classification of CRS in B-NHL and corresponding measures for CRS management, and delineates comprehensive principles and exploratory recommendations for managing anti-CD19 CAR T-cell-associated toxicities in addition to CRS.

keywords

Introduction

CAR T-cell therapy is a novel treatment approach for hematological malignancies1–3. Multiple CD19-targeted CAR T-cell products have been approved for the treatment of relapsed and/or refractory (r/r) B-cell non-Hodgkin lymphoma (B-NHL), including large B-cell lymphoma, follicular lymphoma, and mantle cell lymphoma, in the United States and Europe4–7. In China, 2 CAR T-cell products, axicabtagene ciloleucel8 and relmacabtagene autoleucel9, have been approved for use in adults with r/r large B-cell lymphoma. In addition, the number of registered clinical trials of CAR T cells in China has substantially increased in the past 5 years, and surpassed that in the United States. With the development of novel CAR T-cell products10–12 and innovative approaches, such as dual-target CAR T cells13–15 and sequential infusions of CAR T cells targeting different antigens16–18, CAR T-cell therapy is anticipated to be widely used to treat various tumors beyond B-NHL in the near future.

With increased understanding of CAR T-cell properties and experience in treating patients with CAR T cells, clinicians are becoming more concerned about potentially life-threatening CAR T-cell-associated toxicities19–22. CAR T cells show dynamic differences among hematological malignancies23–26, and CAR T-cell-associated toxicities in B-NHL have distinguishing features such as local cytokine-release syndrome (L-CRS)27. Nevertheless, previously published CRS grading and management guidelines have provided few specific recommendations for managing these toxicities28–30. This consensus aims to provide clinicians with a standardized guideline and recommendations for the diagnosis, prevention, and treatment of toxicities in patients with B-NHL treated with CAR T-cell therapy.

The contents of the consensus are divided into 7 sections: the first section includes a workup and risk assessment for CAR T-cell-associated toxicities at baseline, and the other 6 sections outline various toxicities, including CRS, CAR-T-cell-associated encephalopathy syndrome (CRES), hemophagocytic lymphohistiocytosis/macrophage activation syndrome (HLH/MAS), and other adverse events (AEs). Because CRS is the most commonly observed AE in CAR T-cell therapy, its clinical management is emphasized herein.

Workup and risk assessment for toxicities at baseline

Essential workup procedures before CAR T-cell therapy should include a complete medical history and physical examination, with attention paid to node-bearing areas, evaluation of performance status, documentation of lymphoma classification and staging at diagnosis, previous treatments, and evaluation of opportunistic infections, as appropriate. Laboratory evaluations include complete blood count (CBC), urinalysis, blood chemistry profile, comprehensive metabolic panel, serum ferritin and lactate dehydrogenase, disseminated intravascular coagulation panel (including D-dimer, fibrinogen, prothrombin time, and partial thromboplastin time measurements), serum cytokine profile [including measurements for serum interleukin (IL) 6, tumor necrosis factor-α (TNF-α)], and C-reactive protein. Other recommended tests include hepatitis B/C virus, human immunodeficiency virus, and treponemia pallidum antibody evaluations. Epstein–Barr virus, cytomegalovirus and human herpes virus testing may be useful under certain circumstances. Imaging and other studies include chest/abdomen/pelvic computed tomography (CT) with contrast and/or whole body positron emission tomography/CT, brain magnetic resonance imaging (MRI), electrocardiography, and echocardiography. If any extranodal involvement, particularly in the bone marrow (BM), gastrointestinal (GI) tract, pleura/peritoneum, and central nervous system (CNS), is suspected, relevant examinations, including BM biopsy with aspirate, endoscopic ultrasound, and serosal and lumbar puncture to analyze serosal effusion and cerebrospinal fluid (CSF), should be performed. Organ function tests are recommended for patients with vital organ involvement. Optional workup procedures include BM cytogenetics (karyotype analysis) and pulmonary function tests.

The above workup is also designed to identify populations at higher risk of developing severe toxicities. These high-risk factors include the following: (1) ECOG ≥ 331; (2) age ≥ 70 years; (3) high tumor burden, i.e., the sum of the product of the perpendicular diameters of multiple lesions (SPD) ≥ 100 cm2 32; (4) a bulky mass with diameter ≥ 10 cm; (5) a mass located in the pharynx or around the trachea, with compression symptoms; (6) a mass near luminal organs (e.g., the GI tract or bile duct), which may induce organ dysfunction because of tumor compression and infiltration; (7) serosal involvement with massive serous effusion (pleural/abdominal effusion); (8) hepatitis B antigen seropositivity, hepatitis B virus (HBV) DNA copy number above the upper limit of normal value, or active HBV infection without antiviral treatment; (9) involvement of vital organs (e.g., lung, kidney, or bone marrow); and (10) tumor-associated fever.

CRS

CRS is defined as a supraphysiologic immune response after immunotherapy that leads to overactivation of endogenous or infused T cells and other immune effector cells29,33,34. The incidence rate of CRS among patients with B-NHL treated with CAR T cells is 23%–93%. Among these patients, 2%–22% experience severe CRS (sCRS, grade 3 or higher)8,35,36.

The mechanism of CRS remains elusive. Recent studies have indicated that activated monocytes/macrophages but not CAR T cells are major contributors to CRS37,38, and that endothelial activation and macrophage-released catecholamines may involve amplification of cytokine release and enhancement of inflammatory injury during CAR T-cell therapy39,40. Yuying Liu et al.41 have suggested that damage-associated molecular patterns released by pyroptotic cells may be upstream triggers of macrophage/macrophage activation. Direct contact between CAR T cells and macrophages through CD40-40 L42, CD6943, lymphocyte activation gene-344, and TNF-α45 may also play important roles in this process.

Classification and grading of CRS

Owing to its physiological features, CRS in B-NHL exhibits unique features27,46. Therefore, the classification and grading of CRS in B-NHL must be refined to help clinicians identify and manage this AE effectively.

CRS can be classified as acute CRS (1–3 weeks after infusion), late CRS (3–6 weeks after infusion), and chronic CRS (≥ 6 weeks after infusion) according to the onset time. CRS can also be classified as L-CRS or systemic CRS (S-CRS) according to the location and site, involved 27,47 (Figure 1). During early stages of CAR T-cell therapy, the infused CAR T cells accumulate in the tumor, expand locally, and release several cytokines that in turn trigger a local inflammatory response, which is defined as L-CRS. Subsequently, the locally expanded CAR T cells and cytokines “overflow” into the circulatory system, thereby promoting S-CRS (Figure 2).

CRS staging and classification. CRS can be classified as acute CRS, late CRS, or chronic CRS according to onset time. CRS can also be classified on the basis of the location and site involved as local CRS and systemic CRS. CRS, cytokine-release syndrome; L-CRS, local cytokine-release syndrome; S-CRS, systemic cytokine-release syndrome; CAR, chimeric antigen receptor.
Figure 1

CRS staging and classification. CRS can be classified as acute CRS, late CRS, or chronic CRS according to onset time. CRS can also be classified on the basis of the location and site involved as local CRS and systemic CRS. CRS, cytokine-release syndrome; L-CRS, local cytokine-release syndrome; S-CRS, systemic cytokine-release syndrome; CAR, chimeric antigen receptor.

Schematic diagram of the in vivo distribution of CAR T cells. Schematic procedures from local to systemic CRS after CAR T cell infusion. During early stages after CAR T cell infusion, circulating CAR T cells delivered by intravenous infusion enter the target antigen-expressing tumor mass, thus resulting in CAR T cell expansion and simultaneous cytokine release within locally infiltrating sites, and tumor volume swelling due to local inflammatory reactions; this stage is referred to as clinically local CRS. In the later stage, cytotoxicity of CAR T cells leads to tumor collapse and volume shrinkage; subsequently, many activated CAR T cells and secreted cytokines enter the peripheral blood and trigger systemic CRS.
Figure 2

Schematic diagram of the in vivo distribution of CAR T cells. Schematic procedures from local to systemic CRS after CAR T cell infusion. During early stages after CAR T cell infusion, circulating CAR T cells delivered by intravenous infusion enter the target antigen-expressing tumor mass, thus resulting in CAR T cell expansion and simultaneous cytokine release within locally infiltrating sites, and tumor volume swelling due to local inflammatory reactions; this stage is referred to as clinically local CRS. In the later stage, cytotoxicity of CAR T cells leads to tumor collapse and volume shrinkage; subsequently, many activated CAR T cells and secreted cytokines enter the peripheral blood and trigger systemic CRS.

L-CRS is frequently observed in patients with a high tumor burden or bulky mass, and it manifests as redness/swelling/enlargement and exudation/effusion in or around the lesion, or even perforation or bleeding at the lesion site. Unlike those of L-CRS, the clinical manifestations of S-CRS are characterized by fever, hypotension, and hypoxia, with or without organ dysfunction27,47–49. Given that the previously published CRS grading systems are based only on the severity of S-CRS symptoms, which may not be fully applicable to B-NHL, we propose a new CRS grading system that incorporates the specific manifestations of L-CRS29. The grades are defined by the presence of fever (≥38 °C), the severity of hemodynamic compromise, the severity of hypoxia and the severity of local inflammatory manifestations of lesions surrounding tissues and organs (Table 1).

View this table:
Table 1

Grading of CRS in CAR T-cell treatment for B-NHL

Monitoring and management of acute CRS

The peak window of CRS risk is typically the first 3 weeks after CAR T-cell infusion, which is a critical period for CRS management30. Thus, clinicians must closely monitor patients to ensure early diagnosis and prompt intervention for CRS. The workup includes a complete physical examination, with special attention to vital signs and lesion sites, assessment of organ systems, and laboratory tests19,50. Electrocardiographic monitoring is recommended from the time of CAR T-cell infusion until acute CRS is relieved. For patients with high risk of sCRS, this monitoring should continue for at least 3 weeks or until the high-risk factors are resolved. Laboratory tests include CBC, complete metabolic panel, blood chemistry profile, coagulation profile, serum ferritin, lactate dehydrogenase, serum cytokine profile, and CAR transgene copies (or CAR T-cell percentage in peripheral blood mononuclear cells), which must be rechecked at least 3 times per week for 2 weeks postinfusion, once per week for the next 2 weeks, and every 3 months thereafter. For patients with high sCRS risk, the above tests should be performed more frequently or even daily. Imaging studies to assess the lesions and involved organs may be considered for select patients.

Management of CRS in B-NHL should be performed in line with the grade of this toxicity, as shown in Table 2. If CRS symptoms persist or become aggravated for more than 24 h, a management strategy for a higher CRS grade should be initiated immediately. Patient transfer to the intensive care unit (ICU) is recommended when sCRS develops. In general, patients with CRS are administered a combination of tocilizumab and corticosteroids, in addition to supportive care. For prolonged S-CRS or substantial symptoms or comorbidities, treatment with tocilizumab at 4–8 mg/kg (not exceeding 800 mg) is advised, and administration can be repeated after 6 h, as needed. Furthermore, the use of anti-TNF-α agents can be considered if L-CRS is present or for persistent and refractory fever. For patients with grade 4 or persistent CRS despite anti-IL-6 and/or anti-TNF-α therapy, the use of corticosteroids may be considered. For patients with high risk of sCRS, β-receptor blockers should be administered from the day of CAR T-cell infusion40. Plasma exchange can be performed to treat emergent CRS. Additional supportive care includes antipyretic measures, intravenous fluid boluses, and/or vasopressors for patients with hypotension, and/or supplemental oxygen for those with hypoxia.

View this table:
Table 2

Clinical management of CRS in CAR T-cell treatment of B-NHL29,30

Severe CRS is typically associated with dysfunction in multiple vital organs, such as the heart, liver, and kidney, which can be fatal and should be thoroughly evaluated and properly managed. Of note, L-CRS may cause specific organ damage, depending on the location of the lesion4,51. When L-CRS occurs, patients with GI involvement or lesions around the GI tract may experience mucosal damage or even vascular rupture and bleeding at lesion sites52. Thus, tissue damage may provide more possibilities for the intestinal flora to promote S-CRS; consequently, gut purging and oral antibiotics to inhibit the intestinal flora before CAR T-cell therapy are recommended53. Prophylactic use of anti-TNF-α agents may also be considered when compression symptoms occur in patients with a mass around the trachea or serosal involvement, and anti-TNF-α therapy and local intervention, such as tracheotomy and drainage of serous effusion, should be performed. The heart is another organ requiring special attention54,55: cardiac function should be closely monitored when the tumor lesion is located around the heart56–58. Bridging therapy before CAR T-cell therapy is necessary for patients with this underlying risk. Detailed clinical management procedures for AEs in organs during L-CRS are shown in Table 3.

View this table:
Table 3

Management of AEs in involved organs during L-CRS in CAR T-cell treatment of B-NHL

Late CRS

Late CRS is generally considered delayed acute CRS, typically occurring within 3–6 weeks after CAR T-cell infusion59. Similarly to those of S-CRS, the clinical manifestations of late CRS are fever, cytopenia, elevated transaminase levels, coagulation disorders, increased CAR copy number, and residual tumors. Late CRS should be distinguished from lymphodepletion therapy-associated hematological toxicities, GI toxicities, and infections. The monitoring and management strategies for acute CRS are similar to those for late CRS.

Chronic CRS

Chronic CRS is defined as inflammation- or CAR T-cell-associated AEs that occur after 6 weeks of CAR T-cell infusion29,60,61. The clinical manifestations of chronic CRS include (1) intermittent low-grade fever (below 38 °C); (2) fatigue and anepithymia; (3) cytopenia, particularly thrombocytopenia; (4) CAR T-cell re-expansion in the peripheral blood; (5) residual tumors; and (6) interstitial pneumonitis or bronchiectasis-like manifestations in some patients. Chronic CRS should be distinguished from infections and hematological toxicity59,62. Management of chronic CRS includes anti-TNF-α agents for treatment of pulmonary symptoms and supportive care63. CBC should be monitored closely, and component blood transfusion can be performed for supportive care in select patients.

CAR T-cell-associated encephalopathy syndrome

CRES is another common AE that occurs with CAR T-cell therapy and is characterized by a pathological CNS process after therapy29,64,65. Although the pathophysiological mechanism of CRES remains unclear, its severity has been shown to be associated with high levels of serum cytokines, high tumor burden, disruption of the blood brain barrier, CAR structure, and brain mural cells expressing CD1966,67.

According to published data, the incidence of CRES is 20%–64%, and 5%–28% of cases in patients with B-NHL who receive CAR T-cell therapy are of grade 3 or higher28,35,36,68–70. CRES typically occurs within 8 weeks after CAR T-cell infusion, with a median duration of 4–6 days. Neurological symptoms of CRES include headache, agitation, cognitive dysfunction, tremors, ataxia, language disturbance, somnolence, papilloedema, and seizures30,71,72, and secondary cerebral edema is a leading cause of death47,73.

Distinguishing CRES from cerebrovascular events such as cerebral hemorrhage and infarction is crucial, because thrombocytopenia and coagulation disorders frequently occur after CAR T-cell therapy74. Medical history inquiry and brain MRI examination may be useful. Single epileptic seizures often occur in some patients after CAR T-cell therapy. Clinicians should be cautious when diagnosing CRES, particularly in patients with a history of cerebrovascular accidents and seizures in this context.

According to the CAR-T-cell-therapy-associated toxicity (CARTOX) CRES grading scale30, grade is defined by the CARTOX-10 score, elevated intracranial pressure, and seizures/motor weakness. Workup for grading CRES includes a thorough neurological evaluation through fundoscopic examination and electroencephalography (EEG), neuroimaging assessment through MRI or CT scans, and measurement of CSF pressure30. Similarly to CRS, CRES management should be based on the appropriate toxicity grade, as shown in Table 4. In addition to supportive care, corticosteroids are the cornerstone of the management strategy for CRES. However, tocilizumab is not recommended for treating CRES unless CRS is concurrent. ICU monitoring is recommended for patients with grade 3 or 4 CRES. For patients with a history of seizures or a high risk of CRES, prophylactic use of levetiracetam can be implemented before CAR T-cell therapy73,75.

View this table:
Table 4

Clinical management recommendations for CRES30

Hemophagocytic lymphohistiocytosis/macrophage activation syndrome

HLH/MAS are a group of severe immunological diseases characterized by excessive activation of T cells and macrophages, lymphohistiocytic tissue infiltration, and immune-mediated multiorgan dysfunction76–78. CAR T-cell-associated HLH/MAS usually occurs during the recovery phase of CRS or accompanies CRS29,78,79. Compared with S-CRS, HLH/MAS has characteristic clinical manifestations that include hepatosplenomegaly; hemophagocytes and hemophagocytosis in the bone marrow; cytopenia in at least 2 hematopoietic cell lineages; hypertriglyceridemia; and elevated serum levels of ferritin, cytokines, and soluble CD2580–82. HLH/MAS may result in prolonged leukopenia or neutropenia, thus increasing the risk of serious infection. The early phase of HLH/MAS is easily overlooked, because the features also frequently occur in CRS, infection, and bone marrow suppression after CAR T-cell therapy29,30. HLH/MAS should be suspected in the presence of the following conditions78,80–84: high levels of blood CAR T cells for more than 2 weeks and again after 2 weeks; recurrent fever with cytopenia or hepatosplenomegaly; and sustained increases in serum ferritin. To date, standard clinical management of HLH/MAS in patients treated with CAR T-cell therapy is not well established. According to cumulative experience from multiple domestic centers and consultation with experts with experience in treating this toxicity, we provide the following recommendations for clinical management of HLH/MAS81–84: (1) closely monitor vital signs and CBC in patients after CAR T-cell therapy; (2) closely monitor serum concentrations of ferritin and triglyceride; (3) HLH/MAS should be suspected if a patient has unexplained fever and cytopenia after CAR T-cell infusion; (4) if HLH/MAS is diagnosed, additional therapy with low-dose etoposide (50–100 mg/m2 per week) is recommended; (5) JAK-2 inhibitors (ruxolitinib), CTLA-4 agonists (abatacept), and anti-CD52 antibodies (alemtuzumab) can be used for select patients; (6) plasma exchange may be considered in emergencies; and (7) use of novel agents, such as anti-interferon-γ antibody, may be considered under certain circumstances.

Bone marrow suppression

Cytopenia caused by bone marrow suppression is one of the most common AEs in patients after CAR T-cell therapy70,85–87; the incidence of grade 3–4 neutropenia, anemia, and thrombocytopenia is 45%–69%, 30%–37%, and 15%–30%, respectively9,35,88. At least 15% of patients experience prolonged severe cytopenia beyond 3 months85,86.

Given that cytopenia increases risks of infection and relevant complications (e.g., cerebral hemorrhage), the following management measures should be performed according to its grade: (1) prophylaxis for bacterial and fungal infections until severe leukopenia or neutropenia resolves; (2) supplemental low-flow oxygen and packed red blood cell transfusion for patients with severe anemia; (3) prophylactic use of hemostatic agents and platelet transfusion for patients with severe thrombocytopenia; and (4) additional preventive measures (e.g., room disinfection by ultraviolet light or use of a soft toothbrush) for patients with any grade of leukopenia or thrombocytopenia.

Infection

Infections after CAR T-cell therapy are common and are reported in as many as 70% of patients9,36,59,89; as many as 40% of these infections occur within the first month79. The most common infections are bacterial (16%–30%), and these usually occur within the first 2 weeks. Factors that may contribute to infection include lymphodepletion or prior chemotherapy, CAR T-cell-mediated B-cell aplasia/hypogammaglobulinemia, and prolonged cytopenia.

In such cases, the manifestations of infections can mimic CRS in terms of fever, hypotension, and hypoxia, thus posing a major diagnostic dilemma29,30,90,91. Nonetheless, no biomarkers are available to differentiate the 2 disorders. Moreover, because infections usually occur in the context of CRS and may exacerbate CRS, early identification and timely intervention are crucial. One previous study has indicated that the distinct signature for severe infections includes a double peak of serum IL-6 levels, and high serum levels of IL-8 and IL-1β, which may aid in differential diagnosis between severe infection and CRS51,79. If CRS and infection are not distinguishable, we recommend that the combination of CRS treatment and antimicrobial prophylaxis be considered.

During CAR T-cell therapy, concurrent infections may complicate CAR T-cell-associated toxicities, including CRS and neurotoxicity. Moreover, approximately 10% of severe or life-threatening infections may occur during and after the lymphodepletion period. For patients with active or uncontrolled infection at baseline, CAR T-cell therapy cannot be initiated until the infection is resolved21,70. Prophylaxis against Pneumocystis jirovecii pneumonia and zoster reactivation is generally applied before lymphodepletion therapy and for 3 months thereafter51,92–94. Of note, CAR-T therapy may pose a risk of HBV reactivation in carriers. For HBV carriers, prophylactic use of entecavir should be initiated before lymphodepletion therapy and continue for at least 6 months. Monthly follow-up to monitor HBV DNA levels is also necessary for early detection of HBV reactivation95,96. The decision to provide prophylaxis against bacterial or fungal infections should be risk-adjusted on the basis of patient characteristics, such as prior hematopoietic stem cell transplantation and infection history. After lymphodepletion chemotherapy, the use of granulocyte colony-stimulating factor97 can be considered when neutrophil counts decrease to < 0.5 × 109/L. If infection is suspected, empiric broad-spectrum antibacterial therapy should be initiated immediately98. Empiric antifungal therapy is usually added after 4–7 days in patients expected to have persistent neutropenia.

Infections that occur at specific sites (skin and soft tissue, urinary system, and catheter-associated infections) are more common with CAR T-cell-mediated systemic immunosuppression, in contrast to other antitumor therapies. Of note, infections of the skin and soft tissue or serosal involvement by tumors may be severe and aggravated by concurrent L-CRS. The management principles for special-site infections are provided in Table 5.

View this table:
Table 5

Management of infections at specific sites

Other toxicities

B-cell aplasia/hypogammaglobulinemia

Prolonged B-cell aplasia/hypogammaglobulinemia, an anticipated on-target, off-tumor toxicity, is a characteristic adverse effect after CAR T-cell therapy51,99 that can be diagnosed according to absolute B-cell counts < 61 cells/μL and serum immunoglobulin G (IgG) ≤ 400 mg/dL100. Almost all patients who receive CAR T-cell therapy experience varying degrees of B-cell deficiency36,70, thus increasing the risk of humoral immunity dysfunction-associated infections. Prophylactic intravenous injection of human immunoglobulin (IVIG) is a routine adjuvant treatment for patients who receive CAR T-cell therapy. The practical algorithm for management of hypogammaglobulinemia is as follows93:

  1. Replacement with monthly IVIG until recovery of B cells to the normal range or 6 months after CAR T-cell infusion.

  2. For patients with serum IgG ≤ 400 mg/dL and serious or recurrent infection, monthly IVIG replacement should continue until risk factors are eliminated.

  3. Regular monitoring of serum levels of IgG, IgM and IgA and blood CD19+ or CD20+ B-cell counts is recommended for patients at high risk of infection.

Tumor lysis syndromes

Tumor lysis syndromes (TLS) are a group of disorders caused by rapid release of large amounts of intracellular contents and metabolites into the systemic circulation101,102. Clinical manifestations of TLS include hyperuricemia, hyperphosphatemia, hypocalcemia, hyperkalemia, and acute renal insufficiency. Diagnostic criteria for TLS include (1) a 25% increase in the levels of serum potassium; (2) a 25% decrease in calcium levels; (3) serum creatinine > 221 μmol/L; (4) 25% increase in the levels of serum uric acid or urea nitrogen; and (5) cardiac arrhythmia and renal failure in some patients103,104.

TLS prophylaxis should be considered for patients with high tumor burden (SPD ≥ 100 cm2 or bulky mass with diameter ≥ 10 cm) or high tumor proliferation activity (Ki67 ≥ 85%)101,102. We recommend that hydration and alkalization be initiated 24 h before lymphodepletion therapy, and if necessary, diuretics be used to ensure a urine volume > 3,000 mL/day. Sodium bicarbonate may be administered to maintain urine pH in 7.0–7.5.

The foundation of TLS treatment includes (1) frequent monitoring of electrocardiography, blood pressure, and oxygen saturation; (2) adequate intravenous hydration (≥3,000 mL/day) to maintain urine volume (≥3,000 mL/day), with diuretics used if necessary; (3) sodium bicarbonate administered to ensure urine pH between 7.0 and 7.5; (4) correction of fluid and electrolyte disturbances; (5) allopurinol or febuxostat for treatment of hyperuricemia; and (6) hemodialysis for patients who develop renal failure with uncorrected electrolyte disorder101,102,104,105.

Hypersensitivity reactions

The incidence of infusion-associated allergic reactions is relatively low (up to 3%), and allergic shock rarely occurs. In general, allergic reactions can be easily mistaken for a secondary symptom of other AEs. For example, skin rash usually occurs within the first 2 weeks after CAR T-cell infusion and resolves spontaneously within 3–5 days. In addition to allergies, skin rash may be attributable to CRS-induced increased fragility of the capillary endothelium. The population at high risk of developing allergic reactions includes those who may be hypersensitive to (1) in vitro culture reagents during CAR T production, (2) viral vector impurity, and (3) T-cell activation resulting from a pre-CAR T unresolved inflammatory background.

Management principles include the following: (1) exclusion of patients with hypersensitivity at enrollment; (2) strict control of the procedure and reagents during CAR T-cell manufacturing; (3) antimicrobial therapy before infusion to eliminate an in vivo inflammatory background; and (4) prophylactic use of anti-allergic agents (e.g., diphenhydramine or promethazine)106.

Excessive CAR T-cell proliferation

CAR T-cell levels should be monitored within the first month after CAR T-cell infusion. Blood samples should be collected once every 2–3 days within the first 2 weeks and once per week thereafter. Excessive CAR T-cell proliferation should be highly suspected under the following conditions107: (1) white blood cell counts in peripheral blood ≥ 10 × 109/L; (2) lymphocyte percentage in white blood cells ≥ 70%; and (3) absolute CAR+ T-cell counts > 600 cells/μL. Indications that should be considered for identifying this condition include the following:

  1. Is the expansion of CAR T cells consistent with the changes in tumor size?

  2. Do CAR T cells localize to or expand at other sites in additional to the peripheral blood?

  3. Is the uncontrolled proliferation of activated T cells caused by viral infection?

Management practices to control excessive CAR T-cell proliferation include glucocorticoids and other immunosuppressive agents (e.g., anti-thymocyte globulin or anti-CD52 antibodies). A combination of 2 or more immunosuppressive agents may be used in severe cases.

Secondary malignancies

On the basis of previous studies, the incidence of secondary malignancies after CAR T-cell therapy is approximately 15%59,108, a percentage similar to that of patients receiving other antitumor therapies109–113. Acute myeloid leukemia and myelodysplastic syndromes are the most commonly observed secondary hematologic malignancies28,59,108. Secondary malignancies usually develop after the first year of CAR T-cell therapy114,115, and regular follow-up is important for early recognition of these disorders after CAR T-cell therapy. Some studies have suggested that combination therapy with epigenetic drugs, such as decitabine, may improve patient prognosis.

Conclusions

CAR T-cell therapy is a potentially curative treatment for patients with r/r B-NHL. However, CAR T-cell-associated toxicities may decrease the survival benefit from CAR T-cell therapy. To date, a thorough recommendation for management of CAR T-associated toxicities in B-NHL is lacking. In response to this need, we compiled this consensus on the basis of our current understanding and clinical experience from multiple domestic institutions. The consensus refines the CRS grading system and classification and provides comprehensive and detailed practice recommendations for grading, monitoring, and managing toxicities observed in CAR T-cell therapy for B-NHL. We hope that the consensus will be useful for CAR T-cell therapy for B-NHL by helping clinicians effectively manage CAR T-cell-associated toxicities.

The consensus has several limitations. First, most of the evidence provided was derived from clinical studies on CAR T cells, mostly targeting CD19, yet toxicity profiles and features can vary across CAR T-cell products and individuals. Second, some exploratory recommendations proposed herein are based on case/case series reports or clinical experience, without sufficient evidence. Future multicenter prospective clinical trials and real-world studies are needed to develop more appropriate toxicity mitigation and optimization strategies.

Grant support

This work was supported by funds from the National Natural Science Foundation of China (Grant Nos. 81830002, 81830004, 82070168, and 32070951), the Translational Research grant of NCRCH (Grant No. 2020ZKZC04), and National Key R&D Program of China (Grant No. 2021YFA1100800).

Conflict of interest statement

No potential conflicts of interest are disclosed.

Author contributions

Conceived and designed the analysis: Aibin Liang, Weidong Han, Wenbin Qian.

Collected the data: Ping Li, Yang Liu, Yajing Zhang, Fengxia Shi, Yun Liang.

Contributed data or analysis tools: Aibin Liang, Weidong Han, Wenbin Qian, Ping Li, Yang Liu, Yun Liang, Jian Bo, Sujun Gao, Yongxian Hu, Yu Hu, He Huang, Xiaojun Huang, Hongmei Jing, Xiaoyan Ke, Jianyong Li, Yuhua Li, Qifa Liu, Peihua Lu, Heng Mei, Ting Niu, Yongping Song, Yuqin Song, Liping Su, Sanfang Tu, Jianxiang Wang, Depei Wu, Zhao Wang, Kailin Xu, Zhitao Ying, Qingming Yang, Yajing Zhang, Fengxia Shi, Bin Zhang, Huilai Zhang, Xi Zhang, Mingfeng Zhao, Weili Zhao, Xiangyu Zhao, Liang Huang, Jun Zhu.

Performed the analysis: Ping Li, Yang Liu, Yajing Zhang, Fengxia Shi, Yun Liang.

Wrote the paper: Ping Li, Yang Liu, Yajing Zhang, Fengxia Shi, Yun Liang.

Footnotes

  • ↵*These authors contributed equally to this work.

  • Received September 23, 2022.
  • Accepted December 13, 2022.
https://creativecommons.org/licenses/by/4.0/

This is an open access article distributed under the terms of the Creative Commons Attribution License (CC BY) 4.0, which permits unrestricted use, distribution and reproduction in any medium, provided the original author and source are credited.

References

  1. 1.↵
    2. Grigor EJM,
    3. Fergusson D,
    4. Kekre N,
    5. Montroy J,
    6. Atkins H,
    7. Seftel MD, et al.
    Risks and benefits of chimeric antigen receptor T-cell (CAR-T) therapy in cancer: a systematic review and meta-analysis. Transfus Med Rev. 2019; 33: 98–110.
    OpenUrlPubMed
  2. 2.
    2. Chavez JC,
    3. Locke FL.
    CAR T cell therapy for B-cell lymphomas. Best Pract Res Clin Haematol. 2018; 31: 135–46.
    OpenUrl
  3. 3.↵
    2. Minghan Q,
    3. Shan W,
    4. Xinrui C,
    5. Huaqing W.
    Update on diffuse large B-cell lymphoma: highlights from the 2022 ASCO Annual Meeting. Cancer Biol Med. 2022; 19: 1117–20.
    OpenUrlFREE Full Text
  4. 4.↵
    2. Wei J,
    3. Guo Y,
    4. Wang Y,
    5. Wu Z,
    6. Bo J,
    7. Zhang B, et al.
    Clinical development of CAR T cell therapy in China: 2020 update. Cell Mol Immunol. 2021; 18: 792–804.
    OpenUrlCrossRef
  5. 5.
    2. Reagan PM,
    3. Friedberg JW.
    Axicabtagene ciloleucel and brexucabtagene autoleucel in relapsed and refractory diffuse large B-cell and mantle cell lymphomas. Future Oncol. 2021; 17: 1269–83.
    OpenUrl
  6. 6.
    2. Hayden PJ,
    3. Roddie C,
    4. Bader P,
    5. Basak GW,
    6. Bonig H,
    7. Bonini C, et al.
    Management of adults and children receiving CAR T-cell therapy: 2021 best practice recommendations of the European Society for Blood and Marrow Transplantation (EBMT) and the Joint Accreditation Committee of ISCT and EBMT (JACIE) and the European Haematology Association (EHA). Ann Oncol. 2022; 33: 259–75.
    OpenUrl
  7. 7.↵
    2. Nuvvula S,
    3. Dahiya S,
    4. Patel SA.
    The novel therapeutic landscape for relapsed/refractory diffuse large B cell lymphoma. Clin Lymphoma Myeloma Leuk. 2022; 22: 362–72.
    OpenUrl
  8. 8.↵
    2. Neelapu SS,
    3. Locke FL,
    4. Bartlett NL,
    5. Lekakis LJ,
    6. Miklos DB,
    7. Jacobson CA, et al.
    Axicabtagene ciloleucel CAR T-cell therapy in refractory large B-cell lymphoma. N Engl J Med. 2017; 377: 2531–44.
    OpenUrlCrossRefPubMed
  9. 9.↵
    2. Ying Z,
    3. Yang H,
    4. Guo Y,
    5. Li W,
    6. Zou D,
    7. Zhou D, et al.
    Relmacabtagene autoleucel (relma-cel) CD19 CAR-T therapy for adults with heavily pretreated relapsed/refractory large B-cell lymphoma in China. Cancer Med. 2021; 10: 999–1011.
    OpenUrl
  10. 10.↵
    2. Zhu H,
    3. Deng H,
    4. Mu J,
    5. Lyu C,
    6. Jiang Y,
    7. Deng Q.
    Anti-CD22 CAR-T cell therapy as a salvage treatment in B cell malignancies refractory or relapsed after anti-CD19 CAR-T therapy. Onco Targets Ther. 2021; 14: 4023–37.
    OpenUrl
  11. 11.
    2. Zhang WY,
    3. Wang Y,
    4. Guo YL,
    5. Dai HR,
    6. Yang QM,
    7. Zhang YJ, et al.
    Treatment of CD20-directed chimeric antigen receptor-modified T cells in patients with relapsed or refractory B-cell non-Hodgkin lymphoma: an early phase IIa trial report. Signal Transduct Target Ther. 2016; 1: 16002.
  12. 12.↵
    2. Deng W,
    3. Chen P,
    4. Lei W,
    5. Xu Y,
    6. Xu N,
    7. Pu JJ, et al.
    CD70-targeting CAR-T cells have potential activity against CD19-negative B-cell Lymphoma. Cancer Commun (Lond). 2021; 41: 925–9.
    OpenUrl
  13. 13.↵
    2. Tong C,
    3. Zhang Y,
    4. Liu Y,
    5. Ji X,
    6. Zhang W,
    7. Guo Y, et al.
    Optimized tandem CD19/CD20 CAR-engineered T cells in refractory/relapsed B-cell lymphoma. Blood. 2020; 136: 1632–44.
    OpenUrlCrossRefPubMed
  14. 14.
    2. Zhang Y,
    3. Wang Y,
    4. Liu Y,
    5. Tong C,
    6. Wang C,
    7. Guo Y, et al.
    Long-term activity of tandem CD19/CD20 CAR therapy in refractory/relapsed B-cell lymphoma: a single-arm, phase 1-2 trial. Leukemia. 2022; 36: 189–96.
    OpenUrlCrossRef
  15. 15.↵
    2. Tu S,
    3. Zhou X,
    4. Guo Z,
    5. Huang R,
    6. Yue C,
    7. He Y, et al.
    CD19 and CD70 dual-target chimeric antigen receptor T-cell therapy for the treatment of relapsed and refractory primary central nervous system diffuse large B-cell lymphoma. Front Oncol. 2019; 9: 1350.
    OpenUrlCrossRefPubMed
  16. 16.↵
    2. Sang W,
    3. Shi M,
    4. Yang J,
    5. Cao J,
    6. Xu L,
    7. Yan D, et al.
    Phase II trial of co-administration of CD19- and CD20-targeted chimeric antigen receptor T cells for relapsed and refractory diffuse large B cell lymphoma. Cancer Med. 2020; 9: 5827–38.
    OpenUrl
  17. 17.
    2. Zeng C,
    3. Cheng J,
    4. Li T,
    5. Huang J,
    6. Li C,
    7. Jiang L, et al.
    Efficacy and toxicity for CD22/CD19 chimeric antigen receptor T-cell therapy in patients with relapsed/refractory aggressive B-cell lymphoma involving the gastrointestinal tract. Cytotherapy. 2020; 22: 166–71.
    OpenUrl
  18. 18.↵
    2. Cao Y,
    3. Xiao Y,
    4. Wang N,
    5. Wang G,
    6. Huang L,
    7. Hong Z, et al.
    CD19/CD22 chimeric antigen receptor T cell cocktail therapy following autologous transplantation in patients with relapsed/refractory aggressive B cell lymphomas. Transplant Cell Ther. 2021; 27: 910.e1–11.
    OpenUrl
  19. 19.↵
    2. Los-Arcos I,
    3. Iacoboni G,
    4. Aguilar-Guisado M,
    5. Alsina-Manrique L,
    6. Díaz de Heredia C,
    7. Fortuny-Guasch C, et al.
    Recommendations for screening, monitoring, prevention, and prophylaxis of infections in adult and pediatric patients receiving CAR T-cell therapy: a position paper. Infection. 2021; 49: 215–31.
    OpenUrl
  20. 20.
    2. Schmidts A,
    3. Wehrli M,
    4. Maus MV.
    Toward better understanding and management of CAR-T cell-associated toxicity. Annu Rev Med. 2021; 72: 365–82.
    OpenUrl
  21. 21.↵
    2. Hill JA,
    3. Seo SK.
    How I prevent infections in patients receiving CD19-targeted chimeric antigen receptor T cells for B-cell malignancies. Blood. 2020; 136: 925–35.
    OpenUrlPubMed
  22. 22.↵
    2. Han L,
    3. Zhou J,
    4. Li L,
    5. Zhou K,
    6. Zhao L,
    7. Zhu X, et al.
    Culturing adequate CAR-T cells from less peripheral blood to treat B-cell malignancies. Cancer Biol Med. 2021; 18: 1066–79.
    OpenUrlAbstract/FREE Full Text
  23. 23.↵
    2. Yang X,
    3. Wang GX,
    4. Zhou JF.
    CAR T cell therapy for hematological malignancies. Curr Med Sci. 2019; 39: 874–82.
    OpenUrl
  24. 24.
    2. Holstein SA,
    3. Lunning MA.
    CAR T-cell therapy in hematologic malignancies: a voyage in progress. Clin Pharmacol Ther. 2020; 107: 112–22.
    OpenUrl
  25. 25.
    2. Huang R,
    3. Li X,
    4. He Y,
    5. Zhu W,
    6. Gao L,
    7. Liu Y, et al.
    Recent advances in CAR-T cell engineering. J Hematol Oncol. 2020; 13: 86.
    OpenUrlCrossRefPubMed
  26. 26.↵
    Specialty Committee of Biotherapy tCRHA. Experts consensus on clinical management of toxicity associated with CAR T cell therapy in non-Hodgkin’s lymphoma (NHL). Transl Med. 2021; 10: 1–11.
    OpenUrl
  27. 27.↵
    2. Wei J,
    3. Liu Y,
    4. Wang C,
    5. Zhang Y,
    6. Tong C,
    7. Dai G, et al.
    The model of cytokine release syndrome in CAR T-cell treatment for B-cell non-Hodgkin lymphoma. Signal Transduct Target Ther. 2020; 5: 134.
    OpenUrl
  28. 28.↵
    2. Schuster SJ,
    3. Maziarz RT,
    4. Rusch ES,
    5. Li J,
    6. Signorovitch JE,
    7. Romanov VV, et al.
    Grading and management of cytokine release syndrome in patients treated with tisagenlecleucel in the JULIET trial. Blood Adv. 2020; 4: 1432–9.
    OpenUrlPubMed
  29. 29.↵
    2. Lee DW,
    3. Santomasso BD,
    4. Locke FL,
    5. Ghobadi A,
    6. Turtle CJ,
    7. Brudno JN, et al.
    ASTCT consensus grading for cytokine release syndrome and neurologic toxicity associated with immune effector cells. Biol Blood Marrow Transplant. 2019; 25: 625–38.
    OpenUrlCrossRefPubMed
  30. 30.↵
    2. Neelapu SS,
    3. Tummala S,
    4. Kebriaei P,
    5. Wierda W,
    6. Gutierrez C,
    7. Locke FL, et al.
    Chimeric antigen receptor T-cell therapy - assessment and management of toxicities. Nat Rev Clin Oncol. 2018; 15: 47–62.
    OpenUrlCrossRefPubMed
  31. 31.↵
    2. Oken MM,
    3. Creech RH,
    4. Tormey DC,
    5. Horton J,
    6. Davis TE,
    7. McFadden ET, et al.
    Toxicity and response criteria of the Eastern Cooperative Oncology Group. Am J Clin Oncol. 1982; 5: 649–55.
    OpenUrlCrossRefPubMed
  32. 32.↵
    2. Brepoels L,
    3. Stroobants S,
    4. De Wever W,
    5. Spaepen K,
    6. Vandenberghe P,
    7. Thomas J, et al.
    Aggressive and indolent non-Hodgkin’s lymphoma: response assessment by integrated international workshop criteria. Leuk Lymphoma. 2007; 48: 1522–30.
    OpenUrlCrossRefPubMed
  33. 33.↵
    2. Frey N,
    3. Porter D.
    Cytokine release syndrome with chimeric antigen receptor T cell therapy. Biol Blood Marrow Transplant. 2019; 25: e123–7.
    OpenUrlCrossRefPubMed
  34. 34.↵
    2. Cobb DA,
    3. Lee DW.
    Cytokine release syndrome biology and management. Cancer J. 2021; 27: 119–25.
    OpenUrlPubMed
  35. 35.↵
    2. Abramson JS,
    3. Palomba ML,
    4. Gordon LI,
    5. Lunning MA,
    6. Wang M,
    7. Arnason J, et al.
    Lisocabtagene maraleucel for patients with relapsed or refractory large B-cell lymphomas (TRANSCEND NHL 001): a multicentre seamless design study. Lancet. 2020; 396: 839–52.
    OpenUrlCrossRefPubMed
  36. 36.↵
    2. Schuster SJ,
    3. Bishop MR,
    4. Tam CS,
    5. Waller EK,
    6. Borchmann P,
    7. McGuirk JP, et al.
    Tisagenlecleucel in adult relapsed or refractory diffuse large B-cell lymphoma. N Engl J Med. 2019; 380: 45–56.
    OpenUrlCrossRefPubMed
  37. 37.↵
    2. Giavridis T,
    3. van der Stegen SJC,
    4. Eyquem J,
    5. Hamieh M,
    6. Piersigilli A,
    7. Sadelain M.
    CAR T cell-induced cytokine release syndrome is mediated by macrophages and abated by IL-1 blockade. Nat Med. 2018; 24: 731–8.
    OpenUrlCrossRefPubMed
  38. 38.↵
    2. Norelli M,
    3. Camisa B,
    4. Barbiera G,
    5. Falcone L,
    6. Purevdorj A,
    7. Genua M, et al.
    Monocyte-derived IL-1 and IL-6 are differentially required for cytokine-release syndrome and neurotoxicity due to CAR T cells. Nat Med. 2018; 24: 739–48.
    OpenUrlCrossRefPubMed
  39. 39.↵
    2. Hay KA,
    3. Hanafi LA,
    4. Li D,
    5. Gust J,
    6. Liles WC,
    7. Wurfel MM, et al.
    Kinetics and biomarkers of severe cytokine release syndrome after CD19 chimeric antigen receptor-modified T-cell therapy. Blood. 2017; 130: 2295–306.
    OpenUrlAbstract/FREE Full Text
  40. 40.↵
    2. Staedtke V,
    3. Bai RY,
    4. Kim K,
    5. Darvas M,
    6. Davila ML,
    7. Riggins GJ, et al.
    Disruption of a self-amplifying catecholamine loop reduces cytokine release syndrome. Nature. 2018; 564: 273–7.
    OpenUrlPubMed
  41. 41.↵
    2. Liu Y,
    3. Fang Y,
    4. Chen X,
    5. Wang Z,
    6. Liang X,
    7. Zhang T, et al.
    Gasdermin E-mediated target cell pyroptosis by CAR T cells triggers cytokine release syndrome. Sci Immunol. 2020; 5: eaax7969.
  42. 42.↵
    2. Wagner DH Jr.,
    3. Stout RD,
    4. Suttles J.
    Role of the CD40-CD40 ligand interaction in CD4+ T cell contact-dependent activation of monocyte interleukin-1 synthesis. Eur J Immunol. 1994; 24: 3148–54.
    OpenUrlCrossRefPubMed
  43. 43.↵
    2. McInnes IB,
    3. Leung BP,
    4. Sturrock RD,
    5. Field M,
    6. Liew FY.
    Interleukin-15 mediates T cell-dependent regulation of tumor necrosis factor-alpha production in rheumatoid arthritis. Nat Med. 1997; 3: 189–95.
    OpenUrlCrossRefPubMed
  44. 44.↵
    2. Avice MN,
    3. Sarfati M,
    4. Triebel F,
    5. Delespesse G,
    6. Demeure CE.
    Lymphocyte activation gene-3, a MHC class II ligand expressed on activated T cells, stimulates TNF-alpha and IL-12 production by monocytes and dendritic cells. J Immunol. 1999; 162: 2748–53.
    OpenUrlAbstract/FREE Full Text
  45. 45.↵
    2. Birkland TP,
    3. Sypek JP,
    4. Wyler DJ.
    Soluble TNF and membrane TNF expressed on CD4+ T lymphocytes differ in their ability to activate macrophage antileishmanial defense. J Leukoc Biol. 1992; 51: 296–9.
    OpenUrlPubMed
  46. 46.↵
    2. Mirza AS,
    3. Kumar A,
    4. Hashmi H,
    5. Garcia F,
    6. Logothetis CN,
    7. Darwin A, et al.
    Incidence and management of effusions before and after CD19-directed chimeric antigen receptor (CAR) T cell therapy in large B cell lymphoma. Transplant Cell Ther. 2021; 27: 242.e1–6.
    OpenUrl
  47. 47.↵
    2. Zahid A,
    3. Siegler EL,
    4. Kenderian SS.
    CART cell toxicities: new insight into mechanisms and management. Clin Hematol Int. 2020; 2: 149–55.
    OpenUrl
  48. 48.
    2. Xiao X,
    3. Huang S,
    4. Chen S,
    5. Wang Y,
    6. Sun Q,
    7. Xu X, et al.
    Mechanisms of cytokine release syndrome and neurotoxicity of CAR T-cell therapy and associated prevention and management strategies. J Exp Clin Cancer Res. 2021; 40: 367.
    OpenUrl
  49. 49.↵
    2. Cosenza M,
    3. Sacchi S,
    4. Pozzi S.
    Cytokine release syndrome associated with T-cell-based therapies for hematological malignancies: pathophysiology, clinical presentation, and treatment. Int J Mol Sci. 2021; 22: 7652.
    OpenUrl
  50. 50.↵
    2. Qian WB,
    3. Liu H.
    How I manage B cell lymphoma patients treated with CD19 specific CAR-T cell throughout whole-process management. Chin J Hematol. 2022; 43: 197–202.
    OpenUrl
  51. 51.↵
    2. Brudno JN,
    3. Kochenderfer JN.
    Toxicities of chimeric antigen receptor T cells: recognition and management. Blood. 2016; 127: 3321–30.
    OpenUrlAbstract/FREE Full Text
  52. 52.↵
    2. Cortes-Bullich A,
    3. Perez A,
    4. Bachmeier C,
    5. Mhaskar R,
    6. Chavez JC,
    7. Shah B, et al.
    Outcomes of CD19 chimeric antigen receptor T cell therapy in patients with gastrointestinal tract involvement of large B cell lymphoma. Transplant Cell Ther. 2021; 27: 768.e1–6.
    OpenUrl
  53. 53.↵
    2. Hu Y,
    3. Wang J,
    4. Pu C,
    5. Zhao K,
    6. Cui Q,
    7. Wei G, et al.
    Delayed terminal ileal perforation in a relapsed/refractory B-cell lymphoma patient with rapid remission following chimeric antigen receptor T-cell therapy. Cancer Res Treat. 2018; 50: 1462–6.
    OpenUrl
  54. 54.↵
    2. Alvi RM,
    3. Frigault MJ,
    4. Fradley MG,
    5. Jain MD,
    6. Mahmood SS,
    7. Awadalla M, et al.
    Cardiovascular events among adults treated with chimeric antigen receptor T-cells (CAR-T). J Am Coll Cardiol. 2019; 74: 3099–108.
    OpenUrlFREE Full Text
  55. 55.↵
    2. Burns EA,
    3. Gentille C,
    4. Trachtenberg B,
    5. Pingali SR,
    6. Anand K.
    Cardiotoxicity associated with anti-CD19 chimeric antigen receptor T-cell (CAR-T) therapy: recognition, risk factors, and management. Diseases. 2021; 9: 20.
    OpenUrl
  56. 56.↵
    2. Catino AB.
    Cytokines are at the heart of it: cytokine release syndrome underlies cardiovascular effects of CAR T cell. JACC CardioOncol. 2020; 2: 204–6.
    OpenUrl
  57. 57.
    2. Simbaqueba CC,
    3. Aponte MP,
    4. Kim P,
    5. Deswal A,
    6. Palaskas NL,
    7. Iliescu C, et al.
    Cardiovascular complications of chimeric antigen receptor T-cell therapy: the cytokine release syndrome and associated arrhythmias. J Immunother Precis Oncol. 2020; 3: 113–20.
    OpenUrl
  58. 58.↵
    2. Steiner RE,
    3. Banchs J,
    4. Koutroumpakis E,
    5. Becnel M,
    6. Gutierrez C,
    7. Strati P, et al.
    Cardiovascular events in patients treated with chimeric antigen receptor T-cell therapy for aggressive B-cell lymphoma. Haematologica. 2022; 107: 1555–66.
    OpenUrl
  59. 59.↵
    2. Cordeiro A,
    3. Bezerra ED,
    4. Hirayama AV,
    5. Hill JA,
    6. Wu QV,
    7. Voutsinas J, et al.
    Late events after treatment with CD19-targeted chimeric antigen receptor modified T cells. Biol Blood Marrow Transplant. 2020; 26: 26–33.
    OpenUrlCrossRefPubMed
  60. 60.↵
    2. Porter D,
    3. Frey N,
    4. Wood PA,
    5. Weng Y,
    6. Grupp SA.
    Grading of cytokine release syndrome associated with the CAR T cell therapy tisagenlecleucel. J Hematol Oncol. 2018; 11: 35.
    OpenUrlCrossRefPubMed
  61. 61.↵
    2. Chou CK,
    3. Turtle CJ.
    Assessment and management of cytokine release syndrome and neurotoxicity following CD19 CAR-T cell therapy. Expert Opin Biol Ther. 2020; 20: 653–64.
    OpenUrl
  62. 62.↵
    2. Jain T,
    3. Knezevic A,
    4. Pennisi M,
    5. Chen Y,
    6. Ruiz JD,
    7. Purdon TJ, et al.
    Hematopoietic recovery in patients receiving chimeric antigen receptor T-cell therapy for hematologic malignancies. Blood Adv. 2020; 4: 3776–87.
    OpenUrlCrossRefPubMed
  63. 63.↵
    2. Schubert ML,
    3. Schmitt M,
    4. Wang L,
    5. Ramos CA,
    6. Jordan K,
    7. Müller-Tidow C, et al.
    Side-effect management of chimeric antigen receptor (CAR) T-cell therapy. Ann Oncol. 2021; 32: 34–48.
    OpenUrlCrossRefPubMed
  64. 64.↵
    2. Ying Z,
    3. Huang XF,
    4. Xiang X,
    5. Liu Y,
    6. Kang X,
    7. Song Y, et al.
    A safe and potent anti-CD19 CAR T cell therapy. Nat Med. 2019; 25: 947–53.
    OpenUrlCrossRefPubMed
  65. 65.↵
    2. Takao M.
    Neurotoxicities associated with CAR-T cell therapy. Brain Nerve. 2021; 73: 47–58.
    OpenUrl
  66. 66.↵
    2. Cornillon J,
    3. Hadhoum N,
    4. Roth-Guepin G,
    5. Quessar A,
    6. Platon L,
    7. Ouachée-Chardin M, et al.
    Management of CAR-T cell-related encephalopathy syndrome in adult and pediatric patients: recommendations of the French Society of bone marrow transplantation and cellular therapy (SFGM-TC). Bull Cancer. 2020; 107: S12–7.
    OpenUrl
  67. 67.↵
    2. Parker KR,
    3. Migliorini D,
    4. Perkey E,
    5. Yost KE,
    6. Bhaduri A,
    7. Bagga P, et al.
    Single-cell analyses identify brain mural cells expressing CD19 as potential off-tumor targets for CAR-T immunotherapies. Cell. 2020; 183: 126–42.e17.
    OpenUrlCrossRefPubMed
  68. 68.↵
    2. Westin JR,
    3. Kersten MJ,
    4. Salles G,
    5. Abramson JS,
    6. Schuster SJ,
    7. Locke FL, et al.
    Efficacy and safety of CD19-directed CAR-T cell therapies in patients with relapsed/refractory aggressive B-cell lymphomas: observations from the JULIET, ZUMA-1, and TRANSCEND trials. Am J Hematol. 2021; 96: 1295–312.
    OpenUrlCrossRef
  69. 69.
    2. Cao JX,
    3. Wang H,
    4. Gao WJ,
    5. You J,
    6. Wu LH,
    7. Wang ZX.
    The incidence of cytokine release syndrome and neurotoxicity of CD19 chimeric antigen receptor-T cell therapy in the patient with acute lymphoblastic leukemia and lymphoma. Cytotherapy. 2020; 22: 214–26.
    OpenUrl
  70. 70.↵
    2. Locke FL,
    3. Ghobadi A,
    4. Jacobson CA,
    5. Miklos DB,
    6. Lekakis LJ,
    7. Oluwole OO, et al.
    Long-term safety and activity of axicabtagene ciloleucel in refractory large B-cell lymphoma (ZUMA-1): a single-arm, multicentre, phase 1-2 trial. Lancet Oncol. 2019; 20: 31–42.
    OpenUrlCrossRefPubMed
  71. 71.↵
    2. Hunter BD,
    3. Jacobson CA.
    CAR T-cell associated neurotoxicity: mechanisms, clinicopathologic correlates, and future directions. J Natl Cancer Inst. 2019; 111: 646–54.
    OpenUrlPubMed
  72. 72.↵
    2. Karschnia P,
    3. Jordan JT,
    4. Forst DA,
    5. Arrillaga-Romany IC,
    6. Batchelor TT,
    7. Baehring JM, et al.
    Clinical presentation, management, and biomarkers of neurotoxicity after adoptive immunotherapy with CAR T cells. Blood. 2019; 133: 2212–21.
    OpenUrlAbstract/FREE Full Text
  73. 73.↵
    2. Freyer CW,
    3. Porter DL.
    Cytokine release syndrome and neurotoxicity following CAR T-cell therapy for hematologic malignancies. J Allergy Clin Immunol. 2020; 146: 940–8.
    OpenUrlCrossRefPubMed
  74. 74.↵
    2. Yan Z,
    3. Cao J,
    4. Cheng H,
    5. Qiao J,
    6. Zhang H,
    7. Wang Y, et al.
    A combination of humanised anti-CD19 and anti-BCMA CAR T cells in patients with relapsed or refractory multiple myeloma: a single-arm, phase 2 trial. Lancet Haematol. 2019; 6: e521–9.
    OpenUrlPubMed
  75. 75.↵
    2. Brudno JN,
    3. Kochenderfer JN.
    Recent advances in CAR T-cell toxicity: mechanisms, manifestations and management. Blood Rev. 2019; 34: 45–55.
    OpenUrlPubMed
  76. 76.↵
    2. Al-Samkari H,
    3. Berliner N.
    Hemophagocytic lymphohistiocytosis. Annu Rev Pathol. 2018; 13: 27–49.
    OpenUrlCrossRefPubMed
  77. 77.
    2. Griffin G,
    3. Shenoi S,
    4. Hughes GC.
    Hemophagocytic lymphohistiocytosis: an update on pathogenesis, diagnosis, and therapy. Best Pract Res Clin Rheumatol. 2020; 34: 101515.
  78. 78.↵
    2. Sandler RD,
    3. Tattersall RS,
    4. Schoemans H,
    5. Greco R,
    6. Badoglio M,
    7. Labopin M, et al.
    Diagnosis and management of secondary HLH/MAS following HSCT and CAR-T cell therapy in adults; a review of the literature and a survey of practice within EBMT centres on behalf of the autoimmune diseases working party (ADWP) and transplant complications working party (TCWP). Front Immunol. 2020; 11: 524.
    OpenUrlCrossRefPubMed
  79. 79.↵
    2. Shalabi H,
    3. Gust J,
    4. Taraseviciute A,
    5. Wolters PL,
    6. Leahy AB,
    7. Sandi C, et al.
    Beyond the storm - subacute toxicities and late effects in children receiving CAR T cells. Nat Rev Clin Oncol. 2021; 18: 363–78.
    OpenUrl
  80. 80.↵
    2. Maude SL,
    3. Barrett D,
    4. Teachey DT,
    5. Grupp SA.
    Managing cytokine release syndrome associated with novel T cell-engaging therapies. Cancer J. 2014; 20: 119–22.
    OpenUrlCrossRefPubMed
  81. 81.↵
    2. Teachey DT,
    3. Lacey SF,
    4. Shaw PA,
    5. Melenhorst JJ,
    6. Maude SL,
    7. Frey N, et al.
    Identification of predictive biomarkers for cytokine release syndrome after chimeric antigen receptor T-cell therapy for acute lymphoblastic leukemia. Cancer Discov. 2016; 6: 664–79.
    OpenUrlAbstract/FREE Full Text
  82. 82.↵
    2. Ramos-Casals M,
    3. Brito-Zerón P,
    4. López-Guillermo A,
    5. Khamashta MA,
    6. Bosch X.
    Adult haemophagocytic syndrome. Lancet. 2014; 383: 1503–16.
    OpenUrlCrossRefPubMed
  83. 83.
    2. Lichtenstein DA,
    3. Schischlik F,
    4. Shao L,
    5. Steinberg SM,
    6. Yates B,
    7. Wang HW, et al.
    Characterization of HLH-like manifestations as a CRS variant in patients receiving CD22 CAR T cells. Blood. 2021; 138: 2469–84.
    OpenUrlCrossRefPubMed
  84. 84.↵
    2. Brisse E,
    3. Matthys P,
    4. Wouters CH.
    Understanding the spectrum of haemophagocytic lymphohistiocytosis: update on diagnostic challenges and therapeutic options. Br J Haematol. 2016; 174: 175–87.
    OpenUrl
  85. 85.↵
    2. Fried S,
    3. Avigdor A,
    4. Bielorai B,
    5. Meir A,
    6. Besser MJ,
    7. Schachter J, et al.
    Early and late hematologic toxicity following CD19 CAR-T cells. Bone Marrow Transplant. 2019; 54: 1643–50.
    OpenUrlCrossRefPubMed
  86. 86.↵
    2. Schaefer A,
    3. Huang Y,
    4. Kittai A,
    5. Maakaron JE,
    6. Saygin C,
    7. Brammer J, et al.
    Cytopenias after CD19 chimeric antigen receptor T-cells (CAR-T) therapy for diffuse large B-cell lymphomas or transformed follicular lymphoma: a single institution experience. Cancer Manag Res. 2021; 13: 8901–6.
    OpenUrlCrossRefPubMed
  87. 87.↵
    2. Brudno JN,
    3. Natrakul D,
    4. Lam N,
    5. Dulau-Florea A,
    6. Yuan CM,
    7. Kochenderfer JN.
    Acute and delayed cytopenias following CAR T-cell therapy: an investigation of risk factors and mechanisms. Leuk Lymphoma. 2022; 63: 1849–60.
    OpenUrl
  88. 88.↵
    2. Locke FL,
    3. Miklos DB,
    4. Jacobson CA,
    5. Perales MA,
    6. Kersten MJ,
    7. Oluwole OO, et al.
    Axicabtagene ciloleucel as second-line therapy for large B-cell lymphoma. N Engl J Med. 2022; 386: 640–54.
    OpenUrlCrossRefPubMed
  89. 89.↵
    2. Schuster SJ,
    3. Tam CS,
    4. Borchmann P,
    5. Worel N,
    6. McGuirk JP,
    7. Holte H, et al.
    Long-term clinical outcomes of tisagenlecleucel in patients with relapsed or refractory aggressive B-cell lymphomas (JULIET): a multicentre, open-label, single-arm, phase 2 study. Lancet Oncol. 2021; 22: 1403–15.
    OpenUrlCrossRef
  90. 90.↵
    2. Hill JA,
    3. Li D,
    4. Hay KA,
    5. Green ML,
    6. Cherian S,
    7. Chen X, et al.
    Infectious complications of CD19-targeted chimeric antigen receptor-modified T-cell immunotherapy. Blood. 2018; 131: 121–30.
    OpenUrlAbstract/FREE Full Text
  91. 91.↵
    2. Gudiol C,
    3. Lewis RE,
    4. Strati P,
    5. Kontoyiannis DP.
    Chimeric antigen receptor T-cell therapy for the treatment of lymphoid malignancies: is there an excess risk for infection? Lancet Haematol. 2021; 8: e216–28.
    OpenUrlPubMed
  92. 92.↵
    2. Maude SL,
    3. Frey N,
    4. Shaw PA,
    5. Aplenc R,
    6. Barrett DM,
    7. Bunin NJ, et al.
    Chimeric antigen receptor T cells for sustained remissions in leukemia. N Engl J Med. 2014; 371: 1507–17.
    OpenUrlCrossRefPubMed
  93. 93.↵
    2. Kochenderfer JN,
    3. Dudley ME,
    4. Feldman SA,
    5. Wilson WH,
    6. Spaner DE,
    7. Maric I, et al.
    B-cell depletion and remissions of malignancy along with cytokine-associated toxicity in a clinical trial of anti-CD19 chimeric-antigen-receptor-transduced T cells. Blood. 2012; 119: 2709–20.
    OpenUrlAbstract/FREE Full Text
  94. 94.↵
    2. Lee DW,
    3. Gardner R,
    4. Porter DL,
    5. Louis CU,
    6. Ahmed N,
    7. Jensen M, et al.
    Current concepts in the diagnosis and management of cytokine release syndrome. Blood. 2014; 124: 188–95.
    OpenUrlAbstract/FREE Full Text
  95. 95.↵
    2. Li P,
    3. Zhou L,
    4. Ye S,
    5. Zhang W,
    6. Wang J,
    7. Tang X, et al.
    Risk of HBV reactivation in patients with resolved HBV infection receiving anti-CD19 chimeric antigen receptor T cell therapy without antiviral prophylaxis. Front Immunol. 2021; 12: 638678.
  96. 96.↵
    2. Kusumoto S,
    3. Tobinai K.
    Screening for and management of hepatitis B virus reactivation in patients treated with anti-B-cell therapy. Hematol Am Soc Hematol Educ Program. 2014; 2014: 576–83.
    OpenUrl
  97. 97.↵
    2. Haidar G,
    3. Garner W,
    4. Hill JA.
    Infections after anti-CD19 chimeric antigen receptor T-cell therapy for hematologic malignancies: timeline, prevention, and uncertainties. Curr Opin Infect Dis. 2020; 33: 449–57.
    OpenUrl
  98. 98.↵
    2. Link H,
    3. Böhme A,
    4. Cornely OA,
    5. Höffken K,
    6. Kellner O,
    7. Kern WV, et al.
    Antimicrobial therapy of unexplained fever in neutropenic patients - guidelines of the Infectious Diseases Working Party (AGIHO) of the German Society of Hematology and Oncology (DGHO), Study Group Interventional Therapy of Unexplained Fever, Arbeitsgemeinschaft Supportivmassnahmen in der Onkologie (ASO) of the Deutsche Krebsgesellschaft (DKG-German Cancer Society). Ann Hematol. 2003; 82 Suppl 2: S105–17.
    OpenUrlCrossRefPubMed
  99. 99.↵
    2. Kampouri E,
    3. Walti CS,
    4. Gauthier J,
    5. Hill JA.
    Managing hypogammaglobulinemia in patients treated with CAR-T-cell therapy: key points for clinicians. Expert Rev Hematol. 2022; 15: 305–20.
    OpenUrl
  100. 100.↵
    2. Juluri KR,
    3. Wu QV,
    4. Voutsinas J,
    5. Hou J,
    6. Hirayama AV,
    7. Mullane E, et al.
    Severe cytokine release syndrome is associated with hematologic toxicity following CD19 CAR T-cell therapy. Blood Adv. 2022; 6: 2055–68.
    OpenUrl
  101. 101.↵
    2. Gupta A,
    3. Moore JA.
    Tumor lysis syndrome. JAMA Oncol. 2018; 4: 895.
    OpenUrl
  102. 102.↵
    2. Howard SC,
    3. Jones DP,
    4. Pui CH.
    The tumor lysis syndrome. N Engl J Med. 2011; 364: 1844–54.
    OpenUrlCrossRefPubMed
  103. 103.↵
    2. Rahmani B,
    3. Patel S,
    4. Seyam O,
    5. Gandhi J,
    6. Reid I,
    7. Smith N, et al.
    Current understanding of tumor lysis syndrome. Hematol Oncol. 2019; 37: 537–47.
    OpenUrlPubMed
  104. 104.↵
    2. Coiffier B,
    3. Altman A,
    4. Pui CH,
    5. Younes A,
    6. Cairo MS.
    Guidelines for the management of pediatric and adult tumor lysis syndrome: an evidence-based review. J Clin Oncol. 2008; 26: 2767–78.
    OpenUrlAbstract/FREE Full Text
  105. 105.↵
    2. Muslimani A,
    3. Chisti MM,
    4. Wills S,
    5. Nadeau L,
    6. Zakalik D,
    7. Daw H, et al.
    How we treat tumor lysis syndrome. Oncology (Williston Park). 2011; 25: 369–75.
    OpenUrl
  106. 106.↵
    2. Esmaeilzadeh A,
    3. Tahmasebi S,
    4. Athari SS.
    Chimeric antigen receptor-T cell therapy: applications and challenges in treatment of allergy and asthma. Biomed Pharmacother. 2020; 123: 109685.
  107. 107.↵
    2. Zhang WY,
    3. Liu Y,
    4. Wang Y,
    5. Nie J,
    6. Guo YL,
    7. Wang CM, et al.
    Excessive activated T-cell proliferation after anti-CD19 CAR T-cell therapy. Gene Ther. 2018; 25: 198–204.
    OpenUrl
  108. 108.↵
    2. Cappell KM,
    3. Sherry RM,
    4. Yang JC,
    5. Goff SL,
    6. Vanasse DA,
    7. McIntyre L, et al.
    Long-term follow-up of anti-CD19 chimeric antigen receptor T-cell therapy. J Clin Oncol. 2020; 38: 3805–15.
    OpenUrlCrossRefPubMed
  109. 109.↵
    2. Friedberg JW,
    3. Neuberg D,
    4. Stone RM,
    5. Alyea E,
    6. Jallow H,
    7. LaCasce A, et al.
    Outcome in patients with myelodysplastic syndrome after autologous bone marrow transplantation for non-Hodgkin’s lymphoma. J Clin Oncol. 1999; 17: 3128–35.
    OpenUrlAbstract/FREE Full Text
  110. 110.
    2. Tward JD,
    3. Wendland MM,
    4. Shrieve DC,
    5. Szabo A,
    6. Gaffney DK.
    The risk of secondary malignancies over 30 years after the treatment of non-Hodgkin lymphoma. Cancer. 2006; 107: 108–15.
    OpenUrlCrossRefPubMed
  111. 111.
    2. Travis LB,
    3. Curtis RE,
    4. Glimelius B,
    5. Holowaty E,
    6. Van Leeuwen FE,
    7. Lynch CF, et al.
    Second cancers among long-term survivors of non-Hodgkin’s lymphoma. J Natl Cancer Inst. 1993; 85: 1932–7.
    OpenUrlCrossRefPubMed
  112. 112.
    2. Major A,
    3. Smith DE,
    4. Ghosh D,
    5. Rabinovitch R,
    6. Kamdar M.
    Risk and subtypes of secondary primary malignancies in diffuse large B-cell lymphoma survivors change over time based on stage at diagnosis. Cancer. 2020; 126: 189–201.
    OpenUrlPubMed
  113. 113.↵
    2. Liu Y,
    3. Bewersdorf JP,
    4. Stahl M,
    5. Zeidan AM.
    Immunotherapy in acute myeloid leukemia and myelodysplastic syndromes: the dawn of a new era? Blood Rev. 2019; 34: 67–83.
    OpenUrlCrossRef
  114. 114.↵
    2. Pirani M,
    3. Marcheselli R,
    4. Marcheselli L,
    5. Bari A,
    6. Federico M,
    7. Sacchi S.
    Risk for second malignancies in non-Hodgkin’s lymphoma survivors: a meta-analysis. Ann Oncol. 2011; 22: 1845–58.
    OpenUrlCrossRefPubMed
  115. 115.↵
    2. Morton LM,
    3. Curtis RE,
    4. Linet MS,
    5. Bluhm EC,
    6. Tucker MA,
    7. Caporaso N, et al.
    Second malignancy risks after non-Hodgkin’s lymphoma and chronic lymphocytic leukemia: differences by lymphoma subtype. J Clin Oncol. 2010; 28: 4935–44.
    OpenUrlAbstract/FREE Full Text
Back to top

In this issue

Print
Download PDF
Email Article
Citation Tools

Jump to section

Keywords